WallStSmart
KAPA

Kairos Pharma, Ltd.

AMEX: KAPA · HEALTHCARE · BIOTECHNOLOGY

$0.49
-5.58% today

Updated 2026-06-05

Market cap
$9.21M
P/E ratio
P/S ratio
EPS (TTM)
$-0.30
Dividend yield
52W range
$0 – $2
Volume
0.1M

Kairos Pharma, Ltd. (KAPA) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$98000.00$160000.00$160000.00$160000.00
Gross profit$-98000.00$-160000.00$-160000.00$-160000.00
Gross margin
R&D$20000.00$183000.00$87000.00$82000.00$414000.00$2.13M
SG&A$1.03M$1.66M$324000.00$1.47M$1.93M$3.44M
Operating income$-1.05M$-1.94M$-571000.00$-1.71M$-2.34M$-5.57M
Operating margin
EBITDA$-1.05M$-1.84M$-411000.00$-1.55M$-1.58M$-5.29M
EBITDA margin
EBIT$-1.05M$-1.94M$-571000.00$-1.71M$-1.74M$-5.45M
Interest expense$5411.00$202000.00$479000.00$98000.00$859000.00$0.00
Income tax$-2.60M
Effective tax rate0.0%0.0%0.0%0.0%50.0%0.0%
Net income$-1.05M$-2.15M$-1.05M$-1.81M$-2.60M$-5.45M
Net income growth (YoY)-104.0%+51.0%-72.6%-43.7%-109.3%
Profit margin

Frequently asked questions

How much free cash flow does KAPA generate?

KAPA produced $-3.44M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is KAPA's balance sheet healthy?

KAPA holds $4.49M in cash and equivalents against — in long-term debt, on $6.34M of shareholder equity. That debt is best read against the cash flow the business throws off each year.